NASHVILLE, TN — In a move that signals a robust expansion of funding for Stage IV cancer research, METAVIVOR, a leading non-profit organization dedicated specifically to metastatic breast cancer (MBC), has officially opened its 2026 grant cycle. The announcement comes at a pivotal moment for the oncology community, as the organization grapples with a record-breaking surge in interest from the scientific community and a shifting landscape in federal research funding.
Dr. Kelly Shanahan, President of METAVIVOR and a physician living with MBC, issued the call for applications while participating in a clinical trial at the Sarah Cannon Research Institute in Nashville. Her dual role as both a leader in the advocacy space and a patient on the front lines of experimental medicine underscores the urgency of the organization’s mission: to transition MBC from a terminal diagnosis to a manageable chronic condition through targeted, high-impact research.
Main Facts: A Dual Mandate of Funding and Advocacy
The 2026 grant cycle represents the cornerstone of METAVIVOR’s operational year. Unlike many multi-purpose cancer charities, METAVIVOR is distinguished by its "100% model," in which every penny of every donation goes directly toward research grants for metastatic disease. This focus is critical because, historically, only an estimated 2–5% of overall breast cancer research funding has been directed toward the metastatic stage—the stage responsible for nearly all breast cancer deaths.
Key Highlights of the 2026 Cycle:
- Open Call for Researchers: The organization is actively seeking Letters of Intent (LoIs) from scientists worldwide who are focusing on the unique biological drivers of metastasis.
- Unprecedented Demand: Following a 2025 cycle that saw a 100% increase in LoIs compared to previous years, METAVIVOR is bracing for another record-breaking volume of proposals.
- The Patient-Scientist Review Model: A hallmark of the METAVIVOR process is the inclusion of both PhD-level scientists and trained MBC patients in the grant review process. This ensures that funded research is not only scientifically rigorous but also aligns with the lived priorities of the patient community.
- Clinical Trial Innovation: The organization is highlighting new investigative avenues, specifically a trial led by Dr. Lior Braunstein at Memorial Sloan Kettering (MSK) focused on oligometastatic HER2+ MBC.
Chronology: The Evolution of MBC Research Funding
The trajectory of METAVIVOR’s grant program reflects a broader shift in the oncology landscape. For decades, the primary focus of breast cancer research was early detection and prevention. While these efforts saved countless lives, they often left the 30% of patients who eventually metastasize with limited options.
The Recent Timeline:
- The 2025 Surge: Last year, the organization experienced a "doubling" of LoIs. This spike is attributed to both the growing reputation of METAVIVOR’s peer-review process and a bottleneck in traditional funding sources, such as the National Institutes of Health (NIH).
- Federal Funding Uncertainty: The opening of the 2026 cycle occurs against the backdrop of a proposed federal budget increase for the NIH and the National Cancer Institute (NCI). However, as Dr. Shanahan noted, these increases remain "proposals" until they are codified into law, leaving a gap that private organizations like METAVIVOR must fill.
- Personal and Professional Convergence: Dr. Shanahan’s current residency in Nashville for a clinical trial highlights the "time and financial toxicity" of modern cancer care. Her journey from California to Tennessee reflects the logistical hurdles patients face today as they seek out the next generation of life-extending therapies.
Supporting Data: The Biological and Economic Realities of MBC
To understand the importance of the 2026 grant cycle, one must look at the specific scientific gaps METAVIVOR aims to bridge.
The "Oligometastatic" Breakthrough
A significant portion of the current research focus is on "oligometastatic" disease—a state where a patient has a limited number of metastatic sites (usually five or fewer). Historically, these patients were treated palliatively. However, new data suggests that aggressive intervention might be more effective.
The trial led by Dr. Lior Braunstein at Memorial Sloan Kettering is a prime example of the research METAVIVOR champions. This study investigates whether adding surgical removal of the primary breast tumor and targeted radiation to metastatic sites can improve outcomes for patients with HER2+ MBC. By focusing on this specific subset of the population, researchers hope to prove that "minimal metastases" can be treated with curative intent rather than just symptom management.
The Logistics of "Toxicity"
Dr. Shanahan’s personal experience brings to light the "financial and time toxicity" that data often overlooks:
- Travel Costs: Flying cross-country for treatment involves thousands of dollars in airfare and lodging.
- Time Loss: Patients often spend days traveling for a single infusion or scan, losing precious time with family and support systems.
- Geographic Disparity: The MSK trial is currently limited to New York and New Jersey, though expansion is planned. This geographic concentration of clinical trials creates a barrier to entry for patients in rural or Western regions of the U.S.
Funding Metrics
The NIH/NCI budget is the lifeblood of American medical research. However, the proposed increases are often subject to political gridlock. METAVIVOR’s role is to act as a "venture capitalist" for MBC research, funding high-risk, high-reward pilot studies that can later secure larger federal grants once "proof of concept" is established.
Official Responses: A Call to Action for the Community
In her address, Dr. Shanahan emphasized that the organization’s success is dependent on a three-pronged approach: scientific inquiry, volunteerism, and grassroots fundraising.
On Research Review
"We are always looking for scientists AND patients to review LoIs and full grant applications," Shanahan stated. This dual-review system is designed to democratize the research process. Patients provide the "reality check"—asking whether a particular research project, if successful, would actually improve the quality of life or longevity of someone living with the disease.
On Community Support
METAVIVOR is calling for a surge in volunteerism to meet the demands of the 2026 cycle:
- Fundraising: Supporters planning events in 2026 are urged to coordinate with the central office to utilize the organization’s specialized fundraising platforms.
- Peer Support: The organization is expanding its peer-to-peer support groups. These are not merely social circles; they are led by trained volunteers who help patients navigate the complexities of a metastatic diagnosis.
- Committee Involvement: Beyond research, the organization is seeking volunteers for various committees to handle the administrative and outreach growth necessitated by the increase in grant applications.
On the Clinical Trial Experience
Regarding her time at the Sarah Cannon Research Institute, Dr. Shanahan praised the "Southern hospitality" and the high level of care, but she remained vocal about the need for decentralized trials. "I’m hoping to eventually be able to transfer to a site closer to my home in California," she noted, highlighting a major goal for the advocacy community: making clinical trials accessible in the communities where patients live.
Implications: A Paradigm Shift in Metastatic Care
The opening of the 2026 METAVIVOR grant cycle is more than just an administrative milestone; it is a signal of a paradigm shift in how the medical community views Stage IV cancer.
From Palliative to Proactive
The research funded by these grants—such as Dr. Braunstein’s work on HER2+ MBC—suggests that the "palliative-only" approach is becoming obsolete. By investigating the efficacy of surgery and radiation in the metastatic setting, the oncology field is moving toward a more aggressive, multi-modal strategy that was once reserved only for early-stage patients.
The Power of the Patient Voice
METAVIVOR’s growth proves that patient-led organizations can compete with, and sometimes outpace, traditional institutions in terms of research agility. By involving patients in the grant review process, METAVIVOR ensures that research dollars are not wasted on "ivory tower" projects that have little clinical relevance to those currently fighting for their lives.
The Long-Term Outlook
As the organization looks toward 2026, the goal remains clear: the "cure" for metastatic breast cancer may not be a single "silver bullet" but rather a series of targeted interventions that keep the disease at bay for decades. The doubling of research interest suggests that the scientific community is finally recognizing the complexity—and the opportunity—inherent in metastatic disease.
For the thousands of patients living with MBC, the 2026 grant cycle represents a beacon of hope. As Dr. Shanahan concluded in her message, while the "weather" of a cancer diagnosis can be harsh, the arrival of new research and community support suggests that "good weather will eventually arrive."
About METAVIVOR:
METAVIVOR is a 501(c)(3) non-profit organization dedicated to the specific fight against metastatic breast cancer. It is the only national organization that donates 100% of its net proceeds to metastatic breast cancer research. For more information on how to apply for the 2026 grant cycle, volunteer for a committee, or lead a support group, visit www.metavivor.org.
About the Author
